Header cover image

U.S. Pharmaceuticals & Biotech Low-Risk Leaders

Results

4

0 new
Every great portfolio needs a good foundation. Our selection of stocks can help you lower your risk without sacrificing your returns. Invest in the market's most resilient companies with strong balance sheets and the lowest risk scores in our model.

4 companies

Neurocrine Biosciences

Market Cap: US$16.9b

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

NBIX

US$174.26

7D

6.1%

1Y

35.0%

United Therapeutics

Market Cap: US$23.2b

Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

UTHR

US$555.91

7D

2.3%

1Y

88.8%

Catalyst Pharmaceuticals

Market Cap: US$3.9b

A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

CPRX

US$31.45

7D

-0.2%

1Y

46.6%

Veracyte

Market Cap: US$4.8b

Operates as a diagnostics company in the United States and internationally.

VCYT

US$57.08

7D

-2.5%

1Y

107.5%